[go: up one dir, main page]

WO1999002687A1 - Procede pour augmenter la teneur en fer des cellules des plantes - Google Patents

Procede pour augmenter la teneur en fer des cellules des plantes Download PDF

Info

Publication number
WO1999002687A1
WO1999002687A1 PCT/AU1998/000526 AU9800526W WO9902687A1 WO 1999002687 A1 WO1999002687 A1 WO 1999002687A1 AU 9800526 W AU9800526 W AU 9800526W WO 9902687 A1 WO9902687 A1 WO 9902687A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
plant
sequence
protein
polypeptide
Prior art date
Application number
PCT/AU1998/000526
Other languages
English (en)
Inventor
Marie-Francoise Jardinaud
Elizabeth Salisbury Dennis
William James Peacock
Original Assignee
Commonwealth Scientific And Industrial Research Organisation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific And Industrial Research Organisation filed Critical Commonwealth Scientific And Industrial Research Organisation
Priority to AU81995/98A priority Critical patent/AU8199598A/en
Priority to EP98931829A priority patent/EP1007681A1/fr
Priority to JP2000502183A priority patent/JP2001509385A/ja
Priority to CA002295202A priority patent/CA2295202A1/fr
Publication of WO1999002687A1 publication Critical patent/WO1999002687A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Definitions

  • the present invention relates generally to a method of increasing the nutritive value of an organic foodstuff such as a plant, algae, fungus or other foodstuff to a human or nonhuman animal, by increasing the content of a macronutrient or micronutrient therein using genetic means.
  • the invention relates to a method of increasing the iron content of a plant, algal, fungal or other non-animal or organism.
  • the present invention is particularly useful for the production of a transgenic non-animal having a high macronutrient or micronutrient content.
  • the invention is also useful in the production of a highly nutritive source of macronutrient or micronutrient and in the production of medicated foodstuffs for increasing the bioavailability of a macronutrient or micronutrient to an animal.
  • Iron deficiency is the most prevalent nutritional disorder worldwide, the highest prevalence of iron deficiency occurring in Africa and South East Asia.
  • a Swedish study in 1977 reported that 70% of women of childbearing age on a simple Southeast Asian diet consisting of rice, cooked vegetables and spices, could be estimated to maintain their iron balance only in a state of iron deficiency (Haleberg et al, 1977).
  • 2-4% of Australian women and 3 % of healthy children are anaemic.
  • Approximately 4% of all females could be classed as iron deficient, increasing to 10% if they were pregnant or had donated blood in the last 12 months.
  • Nutritional iron problems associated with vegetarian diets are particularly prevalent in developing countries where major reliance is placed on staple cereals such as rice and wheat, and where intake of animal or fish sources of heme protein are either culturally unacceptable or impractical due to shortage or unreliability of supply, or poverty.
  • the level of heme iron in vegetarian diets is low and much of the iron in vegetarian diets is poorly absorbed due to the presence of factors such as phytates, condensed tannins, certain non-animal proteins, phosphates, oxalates and phosvitin (egg yolk) that may inhibit iron absorption.
  • iron present in plant material has low bioavailability to humans or other animals because it is poorly absorbed.
  • the most highly bioavailable (25%) iron comes from meat and fish in which the heme iron forms myoglobin and hemoglobin.
  • Iron deficiency arises from sustained negative iron balance: the amount of iron absorbed by the body is too low to compensate for the normal physiological requirements.
  • the amount of iron which can be absorbed from the food depends on the quantity and chemical form of iron in the diet and the presence of dietary constituents that modify its absorbability (the amount of iron absorbed also depends of the iron status of the individual).
  • Heme iron which is mainly absent from diets composed primarily of vegetable products has a bioavailibility of approximately 25-35% and is not greatly influenced by the nature of the meal.
  • Non-heme iron has a much greater variability with regard to bioavailibility depending on the nature of the components consumed in a meal.
  • iron deficiency The consequences of iron deficiency are serious and reflect the degree of deficiency. During pregnancy it is associated with low birth weight, premature delivery, prenatal and fetal death. During childhood, it leads to impaired cognitive performance, motor development and decreased linear growth rate. Adults suffer from reduced ability to do physical work. It also impairs the normal defence systems against infection.
  • the inventors sought to increase the bioavailability to humans and other animals, of iron in non-animal foodstuffs, such as plants, fungi and algae, amongst others, by introducing thereto an iron-binding protein molecule.
  • the bioavailability of iron may be increased by introducing a genetic sequence which encodes a heme protein into a plant cell and expressing said genetic sequence therein.
  • One aspect of the invention provides a method of increasing the bioavailable iron content of a non-animal organism, organ, tissue or cell, said method comprising the steps of introducing thereto a genetic sequence which encodes an iron-binding protein and expressing said protein therein for a time and under conditions sufficient for the level of said iron-binding protein to increase.
  • a further aspect of the invention provides a non-animal organism produced using the subject method wherein said non-animal organism or a cell, tissue or organ thereof comprises a higher level of bioavailable iron in a protein-bound form than an otherwise isogenic organism which does not contain the introduced genetic sequence encoding the iron-binding protein.
  • a further aspect of the invention provides a plant produced using the subject method wherein the seed of said plant comprises a higher level of bioavailable iron in a protein-bound form than an otherwise isogenic plant which does not contain the introduced genetic sequence encoding the iron-binding protein.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which is at least about 85% identical to the nucleotide sequence set forth in SEQ ID NO:l or a complementary nucleotide sequence thereto when used to increase the bioavailable iron content in a plant.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which is at least about 85% identical to the nucleotide sequence set forth in SEQ ID NO: 3 or a complementary nucleotide sequence thereto or a homologue, analogue or derivative of said nucleotide sequence which is capable of encoding an iron-binding peptide, polypeptide or protein.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which is at least about 85% identical to the nucleotide sequence set forth in SEQ ID NO:5 or a complementary nucleotide sequence thereto when used to increase the bioavailable iron content in a plant.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which encodes a peptide, polypeptide or protein having at least about 85% amino acid sequence similarity to the sequence set forth in SEQ ID NO:2 when used to increase the bioavailable iron content in a plant.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which encodes an iron-binding peptide, polypeptide or protein having at least about 85% amino acid sequence similarity to the sequence set forth in SEQ ID NO:4.
  • a further aspect of the invention provides an isolated nucleic acid molecule which comprises a nucleotide sequence which encodes a peptide, polypeptide or protein having at least about 85% amino acid sequence similarity to the sequence set forth in SEQ ID NO:6 when used to increase the bioavailable iron content in a plant.
  • a further aspect of the invention provides a cell which has been transformed or transfected with the isolated nucleic acid molecule.
  • a further aspect of the invention provides a plant tissue other than a whole plant regenerated from the cell.
  • a further aspect of the invention provides a method of treatment of iron deficiency in a human or animal subject comprising administering to said subject plant tissue or a derivative thereof having a high bioavailable iron content for a time and under conditions sufficient for the level of iron detectable in the blood of said subject to increase, wherein said plant tissue has a high bioavailable iron content by virtue of the expression therein of an introduced genetic sequence which encodes and iron-binding peptide, polypeptide or protein.
  • Figure 1 is a diagrammatic representation of the plasmid pActl-HbAra-tNOS, which comprises the Arabidopsis thaliana hemoglobin gene (HbAra) placed operably under the control of the actin promoter (pActl) and upstream of the nopaline synthase terminator sequence (tNOS).
  • HbAra Arabidopsis thaliana hemoglobin gene
  • Figure 2 is a diagrammatic representation of the plasmid pGtlfl-HbRice-3'Bt2, which comprises the rice hemoglobin gene (HbRice) placed operably under the control of the rice glutelin promoter (Gtlfl) and upstream of the rice ADP-glucose pyrophosphorylase temiinator sequence (t3'Bt2).
  • HbRice rice hemoglobin gene
  • Figure 3 is a diagrammatic representation of the plasmid pGtlfl-HbAra-3'Bt2, which comprises the Arabidopsis thaliana hemoglobin gene (HbAra) placed operably under the control of the rice glutelin promoter (Gtlfl) and upstream of the rice ADP-glucose pyrophosphorylase terminator sequence (t3'Bt2).
  • HbAra Arabidopsis thaliana hemoglobin gene placed operably under the control of the rice glutelin promoter (Gtlfl) and upstream of the rice ADP-glucose pyrophosphorylase terminator sequence (t3'Bt2).
  • Figure 4 is a diagrammatic representation of the plasmid pActl-HbRice-tNOS, which comprises the rice hemoglobin gene (HbRice) placed operably under the control of the actin promoter (pActl) and upstream of the nopaline synthase terminator sequence (tNOS).
  • HbRice rice hemoglobin gene
  • tNOS nopaline synthase terminator sequence
  • FIG. 5 is a diagrammatic representation of the plasmid pHMW-HbAra-tNOS, which comprises the Arabidopsis thaliana hemoglobin gene (HbAra) placed operably under the control of the HMW promoter (pHM W) and upstream of the nopaline synthase terminator sequence (tNOS).
  • HbAra Arabidopsis thaliana hemoglobin gene
  • FIG 6 is a diagrammatic representation of the plasmid pHMW-HbRice-tNOS, which comprises the rice hemoglobin gene (HbRice) placed operably under the control of the HMW promoter (pHMW) and upstream of the nopaline synthase terminator sequence (tNOS).
  • HbRice rice hemoglobin gene placed operably under the control of the HMW promoter (pHMW) and upstream of the nopaline synthase terminator sequence (tNOS).
  • Figure 7 is a diagrammatic representation of the plasmid pGTl-shlHbRice-tNOS, which comprises the rice hemoglobin gene (HbRice) placed operably under the control of the rice glutelin promoter (pGtl) and downstream of the shrunkenl gene intron 1 sequence (Shi intron) and upstream of the Agrobacterium tumefaciens nopaline synthase terminator sequence (tNOS).
  • HbRice rice hemoglobin gene placed operably under the control of the rice glutelin promoter (pGtl) and downstream of the shrunkenl gene intron 1 sequence (Shi intron) and upstream of the Agrobacterium tumefaciens nopaline synthase terminator sequence (tNOS).
  • Figure 8 is a diagrammatic representation of the plasmid pGTl-shlHbAra-tNOS, which comprises the Arabidopsis thaliana hemoglobin gene (HbAra) placed operably under the control of the rice glutelin promoter (pGtl) and downstream of the shrunkenl gene intron 1 sequence (Shi intron) and upstream of the Agrobacterium tumefaciens nopaline synthase terminator sequence (tNOS).
  • HbAra Arabidopsis thaliana hemoglobin gene
  • pGtl rice glutelin promoter
  • shrunkenl gene intron 1 sequence Shi intron
  • tNOS Agrobacterium tumefaciens nopaline synthase terminator sequence
  • Figure 9 is a schematic representation showing the construction of the expression plasmid pActl-HbAra-tNOS.
  • Figure 10 is a schematic representation showing the construction of the expression plasmid pGtlfl-HbRice-3'Bt2.
  • Figure 11 is a schematic representation showing the construction of the expression plasmid pGtlfl-HbAra-3'Bt2.
  • Figure 12 is a schematic representation showing the construction of the expression plasmid pHMW-HbAra-tNOS.
  • Figure 13 is a schematic representation showing the construction of the expression plasmid pHMW-HbRice-tNOS.
  • Figure 14 is a schematic representation showing the construction of the expression plasmid pGTl-shlHbRice-tNOS.
  • Figure 15 is a schematic representation showing the construction of the expression plasmid pGTl-shlHbAra-tNOS.
  • Figure 16 is a diagrammatic representation of the plasmid pGTl-shl-OSfer-tNOS, which comprises the rice ferritin cDNA (OSfer) placed operably under the control of the rice glutelin promoter (pGtl) and downstream of the shrunkenl gene intron 1 sequence (Shi intron) and upstream of the Agrobacterium tumefaciens nopaline synthase terminator sequence (tNOS).
  • OSfer rice ferritin cDNA
  • pGtl rice glutelin promoter
  • shrunkenl gene intron 1 sequence Shi intron
  • tNOS Agrobacterium tumefaciens nopaline synthase terminator sequence
  • Figure 17 is a diagrammatic representation of the plasmid pGtlfl-OSfer-3'Bt2, which comprises the rice ferritin cDNA (OSfer) placed operably under the control of the rice glutelin promoter (Gtlfl) and upstream of the rice ADP-glucose pyrophosphorylase terminator sequence (t3'Bt2).
  • OSfer rice ferritin cDNA
  • Figure 18 is a diagrammatic representation of the plasmid pWUbi-OSferMito, which comprises the rice ferritin cDNA (OSfer) placed operably under the control of the ubiquitin gene promoter (Ubi) and upstream of the tml sequence.
  • OSfer rice ferritin cDNA
  • Ubi ubiquitin gene promoter
  • FIG 19 is a diagrammatic representation of the plasmid pHMW-OSfer-tNOS, which comprises the rice ferritin cDNA (OSfer) placed operably under the control of the HMW promoter (pHMW) and upstream of the nopaline synthase terminator sequence (tNOS).
  • OSfer rice ferritin cDNA
  • tNOS nopaline synthase terminator sequence
  • Figure 20 is a diagrammatic representation of the plasmid pBxl7-OSfer-tNOS, which comprises the rice ferritin cDNA (OSfer) placed operably under the control of the full-length
  • HMW promoter pBxl7
  • tNOS nopaline synthase terminator sequence
  • Figure 21 is a copy of a photographic representation showing copy number and locus number of the rice hemoglobin cDNA expressed under control of the truncated glutelin promoter (HMW-HbR) in transgenic T 0 rice plants. Lanes marked HMW-HbR (i.e. lanes 3-9 from left in the two left panels and lanes 2-8 in the right panel) contained DNA from transformed rice lines. Lanes marked C contained DNA from an untransformed rice line.
  • Figure 22 is a copy of a Southern blot hybridisation showing hybridisation to the rice hemoglobin cDNA in T , rice plants following transformation with a genetic construct containing the rice hemoglobin cDNA operably under the control of the HMW promoter sequence (i.e. HMW-HbR).
  • the lane marked C contains DNA from an untransformed control rice plant.
  • + indicates the presence of the introduced hemoglobin cDNA;
  • minus sign (-) indicates the absence of the introduced hemoglobin cDNA from the T, line.
  • Figure 23 is a copy of a western blot showing the presence of recombinant hemoglobin in plants transformed with the rice hemoglobin cDNA placed operably under the control of the rice Actinl gene promoter.
  • the arrow indicates the position of the hemoglobin polypeptide.
  • the lane marked C contains DNA from an untransformed control rice plant.
  • Figure 24 is a copy of a western blot showing the presence of recombinant hemoglobin in T2 seed samples of several rice plants transformed with the rice hemoglobin cDNA. In homozygous lines, all seed tested expressed the recombinant hemoglobin polypeptide. In heterozygous lines, recombinant hemoglobin was not detectable in all seed tested. The arrow indicates the position of the hemoglobin polypeptide.
  • the lane marked C contains DNA from an untransformed control rice plant.
  • Figure 25 is a copy of a western blot showing the signal obtained for 5ng, 50ng and 100 ng of purified hemoglobin polypeptide (left panel) compared to the hemoglobin-specific signal obtained for 10-100 ⁇ g of soluble seed protein derived from the seeds of homozygous lines expressing recombinant rice hemoglobin under the control of the GT1 promoter sequence (right panel).
  • Figure 26 is a copy of a western blot (top) and graphical representation (bottom) showing the level of recombinant hemoglobin contained in seed protein extracts derived from homozygous Tl rice lines expressing hemoglobin cDNAs operably under the control of the presence of recombinant hemoglobin in plants transformed with the rice hemoglobin cDNA placed operably under the control of the HMW promoter (HMW-HbR), or the Arabidopsis thaliana hemoglobin cDNA placed operably under the control of either the rice Actinl gene promoter (Act-HbA) or the HMW promoter (HMW-HbA) or the GT1 promoter (GTl-HbA). Taipei is an untransformed control rice plant line. Units of expression are indicated relative to the expression obtained using the HMW promoter to drive expression of the Arabidopsis thaliana hemoglobin cDNA.
  • Figure 27 is a representation of an amino acid sequence alignment between maize ferritin (FM1) and rice ferritin (OSfer) polypeptides.
  • the amino acid sequence of the maize ferritin transit peptide is underlined.
  • the asterisk indicates the cleavage site between the mature subunit and the transit peptide.
  • Figure 28 is a copy of a photographic representation of a western blot showing expression of rice ferritin (OSFer) in two untransformed rice lines (lanes marked Controls- lanes 2-3) and nine transgenic rice lines transformed with the short rice ferritin cDNA (OSFer short) placed under control of the ubiquitin promoter sequence (lanes 4-12). The position of purified recombinant ferritin is indicated in the first lane. For each sample, 50 ⁇ g plant protein or 1 ⁇ g purified recombinant ferritin was loaded onto the gel. Antibodies were used at a dilution of 1 :4000.
  • Figure 29 is a copy of a photographic representation of a western blot showing expression of rice ferritin (OSFer) in three untransformed rice lines (lanes marked Controls- lanes 2-4) and eight transgenic rice lines transformed with the long rice ferritin cDNA (OSFer long) placed under control of the ubiquitin promoter sequence (lanes 5-12). The position of purified recombinant ferritin is indicated in the first lane. For each sample, 50 ⁇ g plant protein or 1 ⁇ g purified recombinant ferritin was loaded onto the gel. Antibodies were used at a dilution of 1 :4000.
  • Figure 30 is a copy of a photographic representation of a western blot showing expression of rice ferritin (OSFer) in different tissues of transgenic rice lines transformed with the long rice ferritin cDNA (OSFer long) placed under control of the ubiquitin promoter sequence (lanes 5-12). The position of purified recombinant ferritin is indicated in the first lane. For each sample, 50 ⁇ g plant protein or 1 ⁇ g purified recombinant ferritin was loaded onto the gel. Antibodies were used at a dilution of 1:4000.
  • Figure 31 is a copy of a photographic representation of a western blot showing expression of rice ferritin (OSFer) in the seeds of transgenic rice lines transformed with the rice ferritin cDNA (OSFer) and in the seeds of untransformed plants (control). The position of purified recombinant ferritin is indicated. For each sample, 50 ⁇ g plant protein or 1 ⁇ g purified recombinant ferritin was loaded onto the gel. Antibodies were used at a dilution of 1:4000.
  • Figure 32 is a copy of a photographic representation showing the expression of recombinant ferritin produced in Escherichia coli and purified recombinant rice ferritin.
  • one aspect of the invention provides a method of increasing the bioavailable iron-content of a non-animal organism such as a plant, fungus, bacterium or algae, amongst others, said method comprising introducing to said organism a a genetic sequence which is capable of expressing an iron-binding protein and expressing said protein therein.
  • bioavailable shall be taken to refer to the availability of a stated integer or group of integers to human or animal organism, including the amount of a stated integer or group of integers which is present in a non-animal organism or foodstuff and which is absorbed in the digestive system or blood of a human or other animal following administration thereto or medicated foodstuff which contains the integer or group of integers.
  • bioavailable iron or “bioavailable iron-content” or similar term shall be taken to refer to the amount of iron, in the ferrous or ferric form, which is present in a non-animal organism or foodstuff and which is absorbed in the digestive system or blood of a human or other animal following administration thereto.
  • non-animal refers to any organism other than a mammal, bird, amphibian, reptile, insect or other animal, or a tissue or cell desirable or derived from said organism.
  • non-animal includes plants, fungi, bacteria and algae.
  • non-animal foodstuff shall be taken to refer to any foodstuff, for nutritional or medical purposes, in liquid or solid form, which is derived from a non-animal source. Accordingly, a non-animal foodstuff includes any solid or liquid vegetable matter or a tonic, elixir, capsule, tablet, powder or solution comprising same, whether suitable for administration to a human or other animal in a ingestible or injectable format.
  • a non-animal foodstuff may be highly-processed such that it is suitable for administration to a human or other animal by injection or ingestion.
  • the present invention encompasses the use of any and all such non-animal foodstuffs.
  • the term "derived from” shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source.
  • the non-animal organism is a plant, in particular an edible plant such as, but not limited to, a cereal, selected from the list comprising rice, wheat, maize, sorghum, rye, barley and millet, or a non-cereal selected from the list comprising legumes, vegetable crop plants and tuber-bearing plants.
  • a cereal selected from the list comprising rice, wheat, maize, sorghum, rye, barley and millet
  • a non-cereal selected from the list comprising legumes, vegetable crop plants and tuber-bearing plants.
  • the plant is a rice plant, even more particularly an indica rice plant such as cultivar selected from the list comprising Arlesienne and Doongarra, amongst others or a japonica rice plant such as cultivar selected from the list comprising Calrose, Millin, Nippon barre, YRM 43 and Jarrah amongst others.
  • indica rice plant such as cultivar selected from the list comprising Arlesienne and Doongarra, amongst others or a japonica rice plant such as cultivar selected from the list comprising Calrose, Millin, Nippon barre, YRM 43 and Jarrah amongst others.
  • the present invention is clearly applicable to altering the bioavailable iron content of any tissue, cell or organ-types derived from a plant according to the embodiments described herein, for example leaf, fruit, seed, root or tuber material, amongst others.
  • iron-binding protein refers to any polypeptide, peptide or a homologue, analogue or derivative thereof which is at least capable of binding iron as Fe 2+ or Fe 3+ , either as free Fe 2+ or Fe 3+ alternatively, in the porphyrin form, for example as iron- porphyrin, iron-protoporphyrin, heme-iron or iron associated with a chlorophyll, cytochrome, cytochrome P 450 or other porphyrin molecule.
  • the iron-binding protein is a heme protein, more preferably a hemoglobin, myoglobin or ferritin polypeptide or a homologue, analogue or derivative thereof.
  • the iron-binding protein is a hemoglobin, it is particularly preferred that the hemoglobin is derived from a plant tissue, still more preferably from a plant tissue other than a nitrogen-fixing nodule.
  • the iron-binding protein is expressed in the plant tissue such that it accumulates in the vacuoles or the apoplastic space.
  • the iron-binding protein comprises a sequence of amino acids set forth in SEQ ID NOS: 2 or 4 or 6 or a homologue, analogue or derivative thereof which possesses iron-binding activity.
  • homologues of an iron-binding protein or an iron-binding polypeptide refer to those polypeptides, enzymes or proteins which have a similar iron- binding activity as the iron-binding protein described herein, notwithstanding any amino acid substitutions, additions or deletions thereto.
  • a homologue may be isolated or derived from the same or another species.
  • amino acids of a homologous polypeptide may be replaced by other amino acids having similar properties, for example hydrophobicity, hydrophilicity, hydrophobic moment, charge or antigenicity, and so on.
  • analogue encompass iron-binding proteins and polypeptides as hereinbefore defined, notwithstanding the occurrence of any non-naturally occurring amino acid analogues therein.
  • derivatives in relation to an iron-binding protein or iron-binding polypeptide as hereinbefore defined shall be taken to refer hereinafter to mutants, parts or fragments of an iron-binding protein or polypeptide to which ligands are attached to one or more of the amino acid residues contained therein, such as carbohydrates, enzymes, proteins, polypeptides or reporter molecules such as radionuclides or fluorescent compounds. Glycosylated, fluorescent, acylated or alkylated forms of the subject peptides are particularly contemplated by the present invention.
  • derivatives of a repressor polypeptide as hereinbefore defined may comprise fragments or parts of an amino acid sequence disclosed herein and are within the scope of the invention, as are homopolymers or heteropolymers comprising two or more copies of the subject polypeptides. Procedures for derivatizing peptides are well-known in the art.
  • a homologue, analogue or derivative of an iron- binding protein or iron-binding polypeptide will possess iron-binding capacity, however it may not perform the same enzymatic function as the iron-binding protein from which it is derived, or to which it is closely related.
  • substitutions encompass amino acid alterations in which an amino acid is replaced with a different naturally-occurring or a non-conventional amino acid residue. Such substitutions may be classified as "conservative", in which case an amino acid residue contained in a repressor polypeptide is replaced with another naturally-occurring amino acid of similar character, for example Gly ⁇ --Ala, Val-t ⁇ Ile-f ⁇ -Leu, Asp ⁇ Glu, Lys ⁇ ->-Arg, Asn ⁇ Gln or Phe ⁇ Trp ⁇ -> yr.
  • substitutions encompassed by the present invention may also be "non-conservative", in which an amino acid residue which is present in an iron-binding polypeptide is substituted with an amino acid having different properties, such as a naturally-occurring amino acid from a different group (eg. substituted a charged or hydrophobic amino acid with alanine), or alternatively, in which a naturally-occurring amino acid is substituted with a non-conventional amino acid.
  • Amino acid substitutions are typically of single residues, but may be of multiple residues, either clustered or dispersed.
  • Naturally-occurring amino acids include those listed in Table 1.
  • Non-conventional amino acids encompassed by the invention include, but are not limited to those listed in Table 2.
  • Amino acid deletions will usually be of the order of about 1-10 amino acid residues, while insertions may be of any length. Deletions and insertions may be made to the N- terminus, the C-terminus or be internal deletions or insertions. Generally, insertions within the amino acid sequence will be smaller than amino-or carboxyl-terminal fusions and of the order of 1-4 amino acid residues.
  • analogues are produced by genetic means wherein genetic sequences which encode the iron-binding protein are mutagenised, such that the resultant polypeptide encoded thereby comprises an altered amino acid sequence.
  • the iron binding protein is a plant-derived hemoglobin.
  • Plant hemoglobins are effective in the performance of the invention by virtue of the fact that each hemoglobin polypeptide is able to bind a single atom of iron.
  • the genetic sequences expressing plant hemoglobin may be derived from any plant organ including the nodules, roots and leaves amongst others.
  • the genetic sequence may be derived from any plant species. In a particularly preferred embodiment however, the species of plant from which the genetic sequence is derived is selected from the list comprising Arabidopsis thaliana, Oryza saliva and maize. TABLE 1
  • Non-conventional Code Non-conventional Code amino acid amino acid
  • D-N-methylcysteine Dnmcys N-(3 , 3-diphenylpropyl) glycine Nbhe D-N-methylglutamine Dnmgln N-(3-guanidinopropyl) glycine Narg
  • D-N-methyllysine Dnmlys N-methyl- ⁇ -aminobutyrate Nmgabu N-methylcyclohexylalanine Nmchexa D-N-methylmethionine Dnmmet D-N-methylornithine Dnmorn N-methylcyclopentylalanine Nmcpen N-methylglycine Nala D-N-methylphenylalanine Dnmphe N-methylaminoisobutyrate Nmaib D-N-methylproline Dnmpro N-( 1 -methy lpropyl)glycine Nile D-N-methylserine Dnmser N-(2-methylpropyl)glycine Nleu D-N-methylthreonine Dnmthr D-N-methyltryptophan Dnmtrp N-( 1 -methy lethy l)glycine Nval D-N-methyltyrosine Dnmtyr N-methyla-napthyla
  • the present invention extends to the use of a genetic sequence encoding a plant hemoglobin which comprises a sequence of nucleotides or is complementary to a sequence of nucleotides substantially as set forth in SEQ ID NO:l or at least 70% identical thereto.
  • the percentage identity to SEQ ID NO:l or a complementary sequence thereto is at least 80%, more preferably at least 90% and still more preferably at least about 99% .
  • the plant-derived hemoglobin or homologue, analogue or derivative thereof comprises a sequence of amino acids substantially as set forth in SEQ ID NO: 2 or at least 70% , preferably at least 80%, more preferably at least 90% and even more preferably at least about 99% similar to SEQ ID NO:2.
  • nucleotide sequence set forth in SEQ ID NO:l relates to the Arabidopsis thaliana hemoglobin genomic gene.
  • the present invention clearly extends to genetic constructs which comprise the complement of SEQ ID NO:l or homologues, analogues or derivatives thereof which may be readily derivable by those skilled in the art.
  • the amino acid sequence set forth in SEQ ID NO: 2 relates to Arabidopsis thaliana hemoglobin, encoded by the gene set forth in SEQ ID NO:l or an equivalent nucleotide sequence, such as a cDNA or RNA molecule, or synthetic DNA molecule.
  • the iron-binding protein is a ferritin peptide, polypeptide or protein, preferably a plant-derived ferritin peptide, polypeptide or protein or a homologue, analogue or derivative thereof.
  • the genetic sequences expressing ferritin may be derived from a maize or a rice plant. Other sources are not excluded.
  • the ferritin genetic sequence or homologue, analogue or derivative thereof comprises a sequence of nucleotides which is at least 85 % identical to the nucleotide sequence set forth in SEQ ID NOS: 3 or 5 or a complementary nucleotide sequence thereof. Even more preferably, the percentage identity to SEQ ID NOS: 3 or 5 is at least 90% , still more preferably at least 95 % and even still more preferably at least 99% or 100% identical to SEQ ID NOS:3 or 5.
  • the plant-derived ferritin peptide, polypeptide or protein or a homologue, analogue or derivative thereof comprises a sequence of amino acids substantially as set forth in SEQ ID NOS: 4 or 6 or is at least 85 % , preferably at least 90% , more preferably at least 95% and even more preferably at least about 99% similar to SEQ ID NOS:4 or 6.
  • the nucleotide sequence set forth in SEQ ID NO:3 relates to the Oryza sativa ferritin cDNA sequence.
  • the nucleotide sequence set forth in SEQ ID NO:5 relates to the ferritin cDNA sequence.
  • the amino acid sequences set forth in SEQ ID NO: 4 and SEQ ID NO: 6 relate to the Oryza sativa and Zea mays ferritin polypeptides, respectively encoded by said cDNA sequences. In detennining whether or not two nucleotide sequences fall within these percentage limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison of nucleotide sequences.
  • nucleotide sequence and amino acid sequence identities or similarities may be calculated using the BESTFIT and GAP programmes, respectively, of the Computer Genetics Group, Inc., University Research Park, Madison, Wisconsin, United States of America (Devereaux et al, 1984).
  • the GAP programme utilizes the algorithm of Needleman and Wunsch (1970) to maximise the number of identical/similar residues and to minimise the number and/or length of sequence gaps in the alignment.
  • the ClustalW programme of Thompson et al. (1994) is used.
  • the genetic sequence which encodes an iron-binding protein as defined herein may be derived from a classical genomic gene, comprising introns and exons or alternatively, the subject genetic sequence may be a cDNA molecule, Expressed Sequence Tag (EST), RNA molecule or a synthetic oligonucleotide molecule, the only requirement being that said genetic sequence, when expressed, is capable of encoding a polypeptide which is capable of binding iron.
  • EST Expressed Sequence Tag
  • the present invention clearly extends to the use of homologues, analogues and derivatives of a hemoglobin or ferritin nucleotide sequence which is at least capable of encoding a polypeptide which binds iron in such a way as to increase the available iron content of a plant cell in which said polypeptide is expressed.
  • the present invention extends further to the use of publicly available genetic sequences not specifically disclosed herein, the only requirement being that such genetic sequences are capable of encoding a polypeptide which binds iron.
  • nucleotide sequence shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as the nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence within said sequence, of one or more nucleotide substitutions, insertions, deletions, or rearrangements.
  • nucleotide sequence set forth herein shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as a nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence of any non-nucleotide constituents not normally present in said isolated nucleic acid molecule, for example carbohydrates, radiochemicals including radionucleotides, reporter molecules such as, but not limited to DIG, alkaline phosphatase or horseradish peroxidase, amongst others.
  • nucleotide sequence set forth herein shall be taken to refer to any isolated nucleic acid molecule which contains significant sequence similarity to said sequence or a part thereof.
  • the nucleotide sequence of the present invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or insertions.
  • Nucleotide insertional derivatives of the nucleotide sequence of the present invention include 5 ' and 3 ' terminal fusions as well as intra-sequence insertions of single or multiple nucleotides or nucleotide analogues.
  • Insertional nucleotide sequence variants are those in which one or more nucleotides or nucleotide analogues are introduced into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed.
  • Deletional variants are characterised by the removal of one or more nucleotides from the nucleotide sequence.
  • Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide or nucleotide analogue inserted in its place. Homologues, analogues and derivatives of the nucleotide sequences set forth in SEQ
  • ID NOS:l, 3 and 5 may be obtained by any standard procedure known to those skilled in the art, such as by nucleic acid hybridization (Ausubel et al, 1987), polymerase chain reaction (McPherson et al, 1991) screening of expression libraries using antibody probes (Huynh et al, 1983) or by functional assay.
  • a suitable cloning vector such as a plasmid or bacteriophage or cosmid molecule
  • Detection is performed preferably by labelling the probe with a reporter molecule capable of producing an identifiable signal, prior to hybridization.
  • reporter molecules include radioactively-labelled nucleotide triphosphates and biotinylated molecules.
  • a low stringency is defined herein as being a hybridisation and/or a wash carried out in 6xSSC buffer, 0.1 % (w/v) SDS at 28°C.
  • the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridisation and/or wash.
  • Conditions for hybridisations and washes are well understood by one normally skilled in the art.
  • variants of the hemoglobin or ferritin gene exemplified herein are isolated by hybridisation under medium or more preferably, under high stringency conditions, to a probe which comprises at least about 30 contiguous nucleotides derived from SEQ ID NOS: 1 or 3 or 5 or a complement thereof.
  • a nucleic acid primer molecule comprising at least about 14 nucleotides in length derived from SEQ ID NOS:l or 3 or 5 or a complementary sequence thereto is hybridized to a nucleic acid template molecule and specific nucleic acid molecule copies of the template are amplified enzymatically as described in
  • protein- or peptide- encoding regions are placed operably under the control of a suitable promoter sequence in the sense orientation, expressed in a prokaryotic cell or eukaryotic cell in which said promoter is operable to produce a peptide or polypeptide, screened with a monoclonal or polyclonal antibody molecule or a derivative thereof against one or more epitopes of a hemoglobin or ferritin polypeptide and the bound antibody is then detected using a detecting means, essentially as described by Huynh et al (1985) which is incorporated herein by reference.
  • Suitable detecting means include 125 I-labelled antibodies or enzyme-labelled antibodies capable of binding to the first-mentioned antibody, amongst others.
  • the present invention clearly extends to any one of the nucleotide sequences set forth in SEQ ID NOS:l or 3 or 5 when used in the inventive method described herein, to increase the bioavailable iron content of a non-animal cell, tissue or organ, in particular a plant cell, tissue or organ.
  • the invention extends further to the use of said nucleotide sequences in producing non-animal cells, tissues and organs having a high bioavailable iron content than is present in otherwise isogenic lines which lack the subject nucleotide sequences or which contain said nucleotide sequences however do not express an iron-binding protein therefrom.
  • the invention extends further to the use of an isolated nucleic acid molecule as described herein to treat iron deficiency in a human or animal subject.
  • the hemoglobin or ferritin genetic sequence may be contained within a genetic construct, such as a plasmid, viral genome, viral sub-genomic fragment, bacteriophage, phagemid or cosmid molecule in a format suitable for expression in a non-animal cell, preferably a plant cell.
  • a genetic construct such as a plasmid, viral genome, viral sub-genomic fragment, bacteriophage, phagemid or cosmid molecule in a format suitable for expression in a non-animal cell, preferably a plant cell. Persons skilled in the art are aware of the requirements for producing such genetic constructs.
  • the present invention clearly extends to genetic constructs which comprise the complement of SEQ ID NOS: 3 or 5 or homologues, analogues or derivatives thereof which may be readily derivable by those skilled in the art, such as a genomic gene equivalent, an RNA molecule, or synthetic DNA molecule, which at least comprises those nucleotide sequences which encode the iron-binding region of ferritin.
  • the genetic constructs used in the performance of the invention comprise, in addition to a genetic sequence which is capable of expressing an iron-binding protein or polypeptide, or a homologue, analogue or derivative thereof, a promoter and optional other regulatory sequences which modulate the expression of the subject genetic sequences.
  • modulation of expression includes the conferring of an appropriate developmental, tissue-specific, cell- specific or organ-specific pattern of expression on the subject genetic sequence. It is also possible to modulate the expression of an iron-binding protein in response to external or environmental stimuli such as heat-shock, hypoxia, flooding, metal ions, antibiotic compounds, amongst others, such that expression of the iron-binding protein may be tightly regulated.
  • Methods for modulation of gene expression are well- within the means of persons of ordinary skill in the art and require no undue experimentation on the part of such persons.
  • To produce a genetic construct which is useful for the present purpose means placing the genetic sequence which encodes an iron-binding protein, in particular the nucleotide sequence set forth in SEQ ID NO: l or SEQ ID NO:3 or SEQ ID NO:5 or a homologue, analogue or derivative thereof, in operable connection with a promoter sequence which is capable of regulating the expression of the subject genetic sequence in a non-animal cell.
  • a promoter sequence which is capable of regulating the expression of the subject genetic sequence in a non-animal cell.
  • promoter is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of the subject genetic sequence in a non-animal cell.
  • the promoter is capable of regulating expression of the genetic sequence in a plant cell, in particular a rice plant cell.
  • Preferred promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression or to alter the spatial expression and/or temporal expression of the genetic sequence which encodes an iron-binding protein.
  • regulatory elements which confer copper inducibility may be placed adjacent to a heterologous promoter sequence driving expression of the subject genetic sequence, thereby conferring copper inducibility on the expression of said molecule.
  • Placing a genetic sequence which encodes an iron-binding protein under the regulatory control of a promoter sequence means positioning the said genetic sequence such that expression is controlled by the promoter sequence. Promoters are generally positioned 5'
  • heterologous promoter/structural gene combinations it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function.
  • the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also occur.
  • promoters suitable for use in genetic constructs of the present invention include viral-, fungal-, bacterial-, animal- and plant- derived promoters capable of functioning in non-animal cells, in particular plant cells such as those described supra.
  • the promoter is capable of expression in a monocotyledonous or dicotyledonous plant cell, for example a cell in a horticultural, vegetable, cereal or agricultural plant.
  • the promoter may regulate the expression of the said genetic sequence constitutively, or differentially with respect to the tissue in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, or plant pathogens, or metal ions, amongst others.
  • promoters examples include the rice Actinl promoter, rice ubiquitin gene promoter, rice glutelin promoter (i.e. GT1 promoter), wheat high molecular weight glutenin (HMW and/or Bxl7) promoter, sucrose synthase promoter, CaMV 35S promoter, NOS promoter, octopine synthase (OCS) promoter, or Arabidopsis thaliana SSU gene promoter, amongst others.
  • rice Actinl promoter i.e. GT1 promoter
  • HMW and/or Bxl7 promoter wheat high molecular weight glutenin promoter
  • sucrose synthase promoter CaMV 35S promoter
  • NOS promoter octopine synthase (OCS) promoter
  • Arabidopsis thaliana SSU gene promoter amongst others.
  • the promoter is the rice ubiquitin promoter, rice glutelin promoter, wheat HMW promoter or rice Actin 1 promoter sequence.
  • Optional additional regulatory sequences may be included in the genetic constructs, for example a terminator sequence placed 3' or downstream of the subject genetic sequence.
  • terminal refers to a DNA sequence at the end of a transcriptional unit encoding an iron-binding protein, wherein said terminator signals termination of transcriptional.
  • Terminators are 3 '-non-translated DNA sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3'- end of a primary transcript. Terminators active in plant cells are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or plants.
  • terminators particularly suitable for use in the genetic constructs of the present invention include the nopaline synthase (NOS) gene terminator of Agrobacterium tumefaciens, the Oryza sativa ADP glucose pyrophosphorylase gene terminator (t3'bt2) the terminator of the Cauliflower mosaic virus (CaMV) 35S gene, the zein gene terminator from Zea mays or the Rubisco small subunit (SSU) gene terminator sequences, amongst others.
  • NOS nopaline synthase
  • t3'bt2 the Oryza sativa ADP glucose pyrophosphorylase gene terminator
  • CaMV Cauliflower mosaic virus
  • SSU Rubisco small subunit
  • the terminator is the t3'bt2 terminator sequence.
  • promoter includes the transcriptional regulatory sequences of a classical prokaryotic or eukaryotic genomic gene, including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner.
  • a promoter is usually, but not necessarily, positioned upstream or 5', of a structural gene, the expression of which it regulates.
  • the regulatory elements comprising a promoter are usually positioned within 2 kb of the start site of transcription of the genetic sequence which encodes an iron-binding protein.
  • the level of expression of the genetic sequence encoding the iron-binding protein or polypeptide may be increased in a plant cell, tissue or organ, by including within the subject genetic construct a nucleotide sequence which comprises an intron derived from a eukaryotic gene and in particular, derived from a plant gene.
  • the intron sequence is placed between the promoter sequence and the genetic sequence to which said promoter is operably connected.
  • the intron sequence is derived from the shrunken-1 gene (.e. the Shi intron).
  • the shrunken-1 gene .e. the Shi intron
  • plant cells which express rice are derived from the shrunken-1 gene (.e. the Shi intron).
  • A. thaliana hemoglobin under the control of the GT-1 promoter sequence accumulate higher levels of hemoglobin if the shl intron sequence is placed downstream of the GT-1 promoter and upstream of the hemoglobin-encoding nucleotide sequence.
  • the present invention further contemplates the use of genetic constructs wherein the iron-binding protein is targeted to an organelle of a plant cell, such as a vacuole, plastid, mitochondria or the endoplasmic reticulum.
  • the Arabidopsis thaliana hemoglobin cDNA is placed operably under the control of the full-length high molecular weight glutenin promoter sequence wherein said promoter sequence contains a known transit peptide or organellar targeting sequence located at its 3 '-end.
  • the recombinant hemoglobin peptide, polypeptide or protein is transported to an organelle in the transgenic plant where it is protected from the action of proteases and accumulates at a higher level than if expressed in the cytosol.
  • the genetic constructs of the invention may further include an origin of replication sequence which is required for replication in a specific cell type, for example a bacterial cell, when said genetic construct is required to be maintained as an episomal genetic element (e.g. plasmid or cosmid molecule) in said cell.
  • origins of replication include, but are not limited to, the i-ori and colEl origins of replication.
  • the genetic construct may further comprise a selectable marker gene or genes that are functional in a cell into which said genetic construct is introduced.
  • selectable marker gene includes any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct of the invention or a derivative thereof.
  • Suitable selectable marker genes contemplated herein include the ampicillin resistance
  • the genetic construct may be introduced into plant tissue, thereby producing a "transgenic plant", by various techniques known to those skilled in the art. The technique used for a given plant species or specific type of plant tissue depends on the known successful techniques.
  • Means for introducing recombinant DNA into plant tissue include, but are not limited to, direct DNA uptake into protoplasts (Krens et al, 1982; Paszkowski et al, 1984), PEG-mediated uptake to protoplasts (Armstrong et al, 1990) microparticle bombardment electroporation (Fromm et al, 1985), microinjection of DNA (Crossway et al. , 1986), microparticle bombardment of tissue explants or cells (Christou et al, 1988; Sanford, 1988) or T-DNA-mediated transfer from Agrobacterium to the plant tissue. Methods for the Agrobacterium- ediated transformation of plants will be well-known to those skilled in the art.
  • a microparticle is propelled into a plant cell, in particular a plant cell not amenable to Agrobacterium mediated transformation, to produce a transformed cell.
  • the cell is a plant cell
  • a whole plant may be regenerated from the transformed plant cell.
  • other non-animal cells derived from multicellular species may be regenerated into whole organisms by means known to those skilled in the art.
  • Any suitable ballistic cell transformation methodology and apparatus can be used in practicing the present invention. Exemplary apparatus and procedures are disclosed by Stomp et al. (U.S. Patent No. 5,122,466) and Sanford and Wolf (U.S. Patent No. 4,945,050).
  • the genetic construct may incorporate a plasmid capable of replicating in the cell to be transformed.
  • microparticles suitable for use in such systems include 1 to 5 ⁇ m gold spheres.
  • the DNA construct may be deposited on the microparticle by any suitable technique, such as by precipitation.
  • Plant species may be transformed with the genetic construct of the present invention by the DNA-mediated transformation of plant cell protoplasts and subsequent regeneration of the plant from the transformed protoplasts in accordance with procedures well known in the art.
  • tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a vector of the present invention.
  • the particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed.
  • Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g. , cotyledon meristem and hypocotyl meristem).
  • organogenesis means a process by which shoots and roots are developed sequentially from meristematic centers.
  • embryogenesis means a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes.
  • Plants of the present invention may take a variety of forms.
  • the plants may be chimeras of transformed cells and non-transformed cells; the plants may be clonal transformants (e.g., all cells transformed to contain the expression cassette); the plants may comprise grafts of transformed and untransformed tissues (e.g. , a transformed root stock grafted to an untransformed scion in citrus species).
  • the transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or Tl) transformed plants may be selfed to give homozygous second generation (or T2) transformed plants, and the T2 plants further propagated through classical breeding techniques.
  • the genetic construct may further incorporate a dominant selectable marker, such as nptll, hygromycin-resistance gene, a phosphinothrium-resistance gene or ampicillin-resistance gene, amongst others, associated with the transforming DNA to assist in cell selection and breeding.
  • a dominant selectable marker such as nptll, hygromycin-resistance gene, a phosphinothrium-resistance gene or ampicillin-resistance gene, amongst others, associated with the transforming DNA to assist in cell selection and breeding.
  • Plants which may be employed in practicing the present invention include all edible plants such as but not limited to, tobacco (Nicotiana tabacum), potato (Solanum tuber osum), soybean (glycine max), peanuts (Arachis hypogaea), cotton (Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot esculenta), coffee (Cofea spp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa (Theobroma cacao), tea (Camellia sinensis), banana (Musa spp.), avocado (Per sea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macad
  • lettuce e.g., Lactuea sativa
  • green beans Phaseolus vulgaris
  • lima beans Phaseolus limensis
  • peas Phase spp.
  • members of the genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and must melon (C. melo) may also be produced.
  • the expression of the introduced gene may be assayed in a transient expression system, or it may be determined after selection for stable integration within the plant genome.
  • Techniques are known for the in vitro culture of plant tissue, and in a number of cases, for regeneration into whole plants. Procedures for transferring the introduced genetic construct from the originally transformed plant into commercially useful cultivars are known to those skilled in the art.
  • transgenic organisms in particular transgenic plants and even more particularly transgenic rice plants which express an iron-binding protein, such as hemoglobin or ferritin, from a genetic construct as described herein are cultured, propagated or otherwise cultivated on an appropriate medium comprising iron in the ferric or ferrous form, in addition to other macronutrients and micronutrients required for the maintenance of the said organism.
  • an iron-binding protein such as hemoglobin or ferritin
  • a further embodiment of the invention provides a method of increasing the bioavailable iron-content of a non-animal organism such as a plant, fungus, bacterium or algae, amongst others, said method comprising the steps of:
  • the medium may be a liquid or solid medium, for example, wherein the transgenic organism is a plant, the medium may be a soil, compost mixture, hydroponic nutrient solution, Murashige and Skoog solid or liquid medium or other plant growth medium available to those skilled in the art.
  • bioavailable concentration of iron is used in the present context to indicate that the iron concentration present in the medium is such that, following uptake by the transgenic organism, the iron concentration delivered to the cell is sufficient to be bound by the iron-binding protein expressed therein.
  • the concentration of iron of the medium is selected such that the concentration of iron delivered to the cell in which the subject iron-binding protein is expressed, is at least equal to the K m of said iron-binding protein for iron, in the form in which it is contained in the medium, or equal to the K m of the iron-binding protein for heme- iron. More preferably, the iron concentration delivered to the cell is 2-fold the K m of the iron-binding protein for iron in the form in which it is contained in the medium or heme-iron. Even more preferably, the iron concentration delivered to the cell is sufficient to fully saturate the iron-binding protein with iron in the form in which it is present in the medium, or to fully saturate the iron-binding protein with heme-iron.
  • a further aspect of the present invention provides a transgenic non-animal organism having a high bioavailable iron-content wherein said organism has been produced according to the methods described herein.
  • the transgenic non- animal organism of the invention contains a significantly higher level of iron, present as heme-iron or free Fe 2+ or Fe 3+ , than do isogenic isolates of the same organism which do not express the foreign iron-binding protein introduced thereto.
  • the transgenic non-animal organism is a plant, more preferably a rice plant. Other plants are not excluded .
  • the present invention extends to the progeny cells, tissues, organs and organisms of the said transgenic non-animal organism.
  • the transgenic non-animal organism may be administered to a human or animal subject as food or in feed or it may be processed to produce a medicated foodstuff suitable for administration to a human or other animal suffering from an iron deficiency, as a result of inadequate dietary iron intake, medical illness or menstruation, amongst other conditions.
  • a further aspect of the invention contemplates a medicated foodstuff suitable for the treatment of iron-deficiency in humans or other animals wherein said medicated foodstuff comprises iron as an active compound derived from a transgenic non- animal organism produced according to any of the embodiments described herein.
  • a further aspect of the present invention contemplates a method of treating an iron deficiency in a human or non-human animal, said method comprising administering to a human or non-human animal suffering from said iron-deficiency a medicated foodstuff produced essentially as described herein.
  • Medicated foodstuffs prepared from the genetically-transformed non-animal organism may be administered orally or injected in any convenient manner.
  • Oral administration is usually in the form of a liquid iron tonic, a capsule, tablet or powder.
  • the active compounds may also be administered in dispersions prepared in glycerol, liquid polyethylene glycols, and/or mixmres thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for parenteral administration include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example.
  • Sterile injectable solutions are prepared by incorporating the iron derived from the non-animal transgenic organism in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilisation.
  • dispersions are prepared by incorporating the various sterilised active ingredient(s) into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • Carriers and/or diluents suitable for veterinary use include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the composition is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • a still further aspect of the present invention provides an isolated ferritin gene which comprises a sequence of nucleotides or is complementary to a sequence of nucleotides substantially as set forth in SEQ ID NO: 3 or a homologue, analogue or derivative thereof which is at least about 85% identical to SEQ ID NO: 3 or a complementary sequence thereto.
  • the percentage similarity to a sequence set forth in SEQ ID NOS:l or 3 is at least 90% . Even more preferably, the percentage identity is at least 95% . Still more preferably, the percentage identity is at least 99% .
  • a “gene” is to be taken in its broadest context and includes: (i) a classical genomic gene consisting of a coding region optionally together with transcriptional and/or translational regulatory sequences and a coding region with or without non-translated sequences (i.e. introns, 5'- and 3'- untranslated sequences); and/or
  • a functional product is a protein or polypeptide or derivative thereof which is capable of binding iron and, as a consequence, is useful for the purpose of the present invention as stated herein.
  • the genetic sequences which encode rice ferritin may correspond to the naturally occurring sequence or may differ by one or more nucleotide substitutions, deletions and/or additions. Accordingly, the present invention extends to iron-binding genes and any functional genes, mutants, derivatives, parts, fragments, homologues or analogues thereof.
  • Preferred genes according to this aspect of the invention are capable of encoding an iron-binding polypeptide.
  • Preferred homologues, analogues and derivatives of the rice ferritin cDNA sequence set forth in SEQ ID NO: 3 will be derived from a naturally occurring ferritin genes by standard recombinant techniques.
  • the rice ferritin gene may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or additions.
  • Nucleotide insertional derivatives of the iron-binding gene of the present invention include 5' and 3' terminal fusions as well as intra-sequence insertions of single or multiple nucleotides.
  • Insertional nucleotide sequence variants are those in which one or more nucleotides are introduced into a predetermined site in the nucleotide sequence although random insertion is also possible with suitable screening of the resulting product.
  • Deletional variants are characterised by the removal of one or more nucleotides from the sequence.
  • Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide inserted in its place.
  • substitution may be "silent" in that the substitution does not change the amino acid defined by the codon.
  • substituents are designed to alter one amino acid for another similar acting amino acid, or amino acid of like charge, polarity, or hydrophobicity.
  • the present invention extends to the isolated nucleic acid encoding rice ferritin when integrated into a plant genome and to propagated plants derived therefrom which comprise the introduced rice ferritin gene.
  • the present invention contemplates a nucleic acid molecule which encodes an iron-binding protein and which is capable of hybridising under at least moderate or high stringency conditions to the nucleic acid molecule set forth in SEQ ID NO: 3 or a complementary sequence thereto.
  • Hb Rice and the Arabidopsis thaliana hemoglobin (HbAra) cDNAs were inserted into constructs suitable for introduction into rice by particle gun bombardment or Agrobacterium-mediated transformation.
  • the two sequences were placed downstream of constitutive promoters (the promoter of the rice Actin gene and the promoter of the rice Ubiquitin gene, or a seed-specific truncated rice glutelin promoter (GTl) with a Shi intron, the full length GTl promoter, a truncated wheat high molecular weight glutenin promoter (HMW) and the full length wheat high molecular weight glutenin promoter (Bxl7).
  • constitutive promoters the promoter of the rice Actin gene and the promoter of the rice Ubiquitin gene, or a seed-specific truncated rice glutelin promoter (GTl) with a Shi intron
  • GTl seed-specific truncated rice glutelin promoter
  • HMW trunc
  • Plasmids which express the rice hemoglobin (HbRice) protein under the control of the glutelin, Actinl or HMW promoter sequences are shown in Figures 2, 4 and 6, respectively.
  • the genetic construct comprises, in addition to the GTl promoter sequence, the intron 1 sequence of the maize shrunkenl gene.
  • All plasmids comprising the HbAra sequence utilised the nopaline synthase terminator gene terminator of Agrobacterium tumefaciens (tNOS) or the Oryza sativa ADP glucose pyrophosphorylase gene terminator (t3'Bt2).
  • the hemoglobin constructs were introduced into rice via particle bombardment and, in the case of the construct containing A. thaliana hemoglobin under control of the Bxl7 promoter, using Agrobacterium-mediated transformation procedures. Plants were regenerated. The number of lines obtained for each construct is given in Table 3.
  • Callus were also generated from mature seed of the Australian rice cultivars Jarrah, Millin and YRM13 for transformation with the Arabidopsis thaliana hemoglobin cDNA, placed operably under the control of the full-length wheat high molecular weight glutenin promoter sequence. Taipei was used as a control for the transformation and regeneration efficiencies.
  • a genetic construct comprising the A. thaliana hemoglobin cDNA operably under control of the full-length HMW promoter was introduced into callus by particle bombardment or Agrobacterium-mediated transformation. In a preliminary experiment, plants were regenerated from Jarrah calli which had been bombarded with this genetic construct.
  • Tl seeds from overexpressing lines were germinated, and after 5 months seeds from those plants were collected (T2 seeds).
  • proteins were extracted from 20 seeds and their individual protein content analysed immunologically using antibodies against hemoglobin. Using this method homozygous transgenic lines were identified.
  • the level of hemoglobin in the seeds of transgenic homozygous and heterozygous lines was estimated using western blotting (Figure 24). By comparing the expression level of hemoglobin in homozygous lines against a hemoglobin protein standard (Figure 25), it was possible to quantitate the expression level (Figure 26). Highest seed expression levels of hemoglobin were observed for homozygous rice lines expressing A. thaliana hemoglobin under control of the GTl promoter sequence. Transgenic lines were found to contain 0.5 to 1.5 ng of hemoglobin per ⁇ g of soluble seed proteins. These quantities are 15 to 85 times greater than what is present in non transformed seeds (Figure 5). The most effective promoter was the full length rice glutelin promoter (1.5 ng of hemoglobin per ⁇ g of soluble seed proteins). TABLE 4 Characterisation of hemoglobin-overexpressing lines
  • the rice ferritin cDNA was identified by searching the Rice Expressed Sequence Tag (EST) database.
  • the single partial length cDNA was showing a strong homology to maize ferritin 1 cDNA (FM1; SEQ ID NO: 5) and maize ferritin 2 cDNA (FM2).
  • An IR54 cDNA library from anaerobically-treated cells was screened using the EST as a probe and allowed the isolation of a full length rice ferritin cDNA (OSFer; SEQ ID NO: 3).
  • the FM1 sequence is 1139 nucleotides long (ATG-polyA sequence) and contain an open reading frame of 254 amino acids.
  • a 3' untranslated region of 380 nucleotides is found downstream of a stop codon and a putative polyA+tail was found.
  • the sequence of a putative chloroplast-type transit peptide has been identified (amino acid residues 1 to 43).
  • the OSfer sequence is 987 nucleotides long and contain an open reading frame of 197 amino acids.
  • Osfer ferritin protein has 83.85% identity with the maize ferritin protein ( Figure 27).
  • OSfer cDNA was modified by PCR: a second ATG was introduced in frame with the endogenous one. BamHl sites were introduced just before the ATG and just before the beginning of the putative poly A + tail (OSfer long) or just after the stop codon (OSfer short). OSfer long and OSfer short were inserted into constructs suitable for introduction into rice by particle gun bombardment or Agrobacterium-mediated transformation.
  • the two sequences were placed downstream of a constitutive promoter (the promoter of the rice Ubiquitin gene) and seed-specific promoters: a truncated rice glutelin promoter (GTl) with a Shi intron, the full length GTl promoter, a truncated wheat high molecular weight glutenin promoter (HMW) and the full length wheat high molecular weight glutening promoter (Bxl7).
  • a constitutive promoter the promoter of the rice Ubiquitin gene
  • seed-specific promoters seed-specific promoters: a truncated rice glutelin promoter (GTl) with a Shi intron, the full length GTl promoter, a truncated wheat high molecular weight glutenin promoter (HMW) and the full length wheat high molecular weight glutening promoter (Bxl7).
  • the ferritin constructs were introduced into rice via particle bombardment. Plants were regenerated. The number of lines obtained for each construct is given in Table 5.
  • Antibodies were tested on 9 young T 0 plants which were transformed using the
  • Rats are maintained on an iron-deficient diet for 2-3 weeks. Approximately 2.5 kilograms of transgenic rice seed over-expressing recombinant rice ferritin or hemoglobin is collected and fed to 6 iron-deficient rats, each consuming 20g feed per day comprising 70% rice balance, over a total period of 4 weeks. Control lines of iron-deficient rats are fed on untransformed, otherwise isogenic rice seed. Hemoglobin repletion is assayed after 4 weeks to determine the effect of the transgenic rice diet on overcoming iron-deficiency.
  • Pigs are naturally anaemic animals and normally receive an iron injection at birth.
  • the gastrointestinal tract of the pig is similar to the human gastrointestinal tract and pigs will consume a diet typical of that eaten by humans.
  • the pig is a suitable model for assessing the bioavailability of iron in a human diet.
  • a population of pigs is maintained on an iron-deficient diet until anaemic.
  • Transgenic rice seed over-expressing recombinant rice ferritin or hemoglobin is collected and fed to iron- deficient pigs, each consuming a diet comprising 70% rice balance, over a total period of about 4 weeks.
  • Control anaemic animals are fed on untransformed, otherwise isogenic rice seed.
  • a second population of control non-anaemic animals is also fed on the transformed rice seed or untransformed rice seed.
  • Hemoglobin repletion is assayed after 4 weeks to determine the effect of the transgenic rice diet on overcoming anaemia. Additionally, tissue samples and gut contents are analysed.
  • OSfer short was inserted into an expression vector pQE30.
  • the 6xHis coding sequence was placed in frame at the 5' end of OSfer short.
  • the recombinant protein was expressed and purified ( Figure 32). It was then used to generate rabbit anti-OSfer.
  • TELECOMMUNICATION INFORMATION (A) TELEPHONE: 61 3 9254 2777 (B) TELEFAX: 61 3 9254 2770 (2) INFORMATION FOR SEQ ID NO : 1 :
  • MOLECULE TYPE DNA (genomic)
  • ORGANISM Arabidopsis thaliana
  • gagactcacc aattcctgct gagcaaaatc caaagctcaa gcctcacgca atgtctgttt 360
  • gac cgt gac aac gtt get etc aag gga ttc gcc aaa ttc ttc aaa gaa 384 Asp Arg Asp Asn Val Ala Leu Lys Gly Phe Ala Lys Phe Lys Glu 115 120 125
  • ctt gag gaa gaa get tgaatggagg agacggtgtg aagggcagta gtaggtttcg 631 Leu Glu Glu Glu Ala 195
  • cct get ccc gtc gtc agg gtg gcg gcg ccg cgc gga gtc gcc teg ccg 210 Pro Ala Pro Val Val Arg Val Ala Ala Pro Arg Gly Val Ala Ser Pro 25 30 35
  • gtg get etc aaa gga ttt gcc aag ttc ttc aag gaa tec age gac gag 498 Val Ala Leu Lys Gly Phe Ala Lys Phe Phe Lys Glu Ser Ser Asp Glu 120 125 130 135 gag agg gag cac get gaa aag cte atg gag tac cag aac aaa cgt gga 546 Glu Arg Glu His Ala Glu Lys Leu Met Glu Tyr Gin Asn Lys Arg Gly 140 145 150

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé pour augmenter la teneur en fer biodisponible de cellules, de tissus ou d'organes de non animaux. Ce procédé consiste à introduire une séquence génétique qui code une protéine de liaison au fer, de préférence, une séquence génétique qui code une protéine de liaison à l'hème telle que l'hémoglobine ou la ferritine, pendant un laps de temps et dans des conditions permettant l'augmentation de la teneur de cette protéine de liaison au fer. Les cellules non animales transformées, les tissus et les organes produits selon ce procédé présentent une valeur nutritive améliorée pour l'animal et l'homme, en particulier, pour lutter contre l'anémie et les effets de l'anémie. L'invention a aussi pour objet une nouvelle séquence génétique dérivée du riz, qui code un polypeptide de ferritine, en autres, pour mettre en oeuvre le procédé selon l'invention.
PCT/AU1998/000526 1997-07-08 1998-07-08 Procede pour augmenter la teneur en fer des cellules des plantes WO1999002687A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU81995/98A AU8199598A (en) 1997-07-08 1998-07-08 Method of increasing the iron content of plant cells
EP98931829A EP1007681A1 (fr) 1997-07-08 1998-07-08 Procede pour augmenter la teneur en fer des cellules des plantes
JP2000502183A JP2001509385A (ja) 1997-07-08 1998-07-08 植物細胞の鉄分含有量を高める方法
CA002295202A CA2295202A1 (fr) 1997-07-08 1998-07-08 Procede pour augmenter la teneur en fer des cellules des plantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7766 1997-07-08
AUPO7766A AUPO776697A0 (en) 1997-07-08 1997-07-08 Method of increasing the iron content of plant cells

Publications (1)

Publication Number Publication Date
WO1999002687A1 true WO1999002687A1 (fr) 1999-01-21

Family

ID=3802054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1998/000526 WO1999002687A1 (fr) 1997-07-08 1998-07-08 Procede pour augmenter la teneur en fer des cellules des plantes

Country Status (5)

Country Link
EP (1) EP1007681A1 (fr)
JP (1) JP2001509385A (fr)
AU (1) AUPO776697A0 (fr)
CA (1) CA2295202A1 (fr)
WO (1) WO1999002687A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372961B1 (en) 1998-08-20 2002-04-16 Pioneer Hi-Bred International, Inc. Hemoglobin genes and their use
KR100419530B1 (ko) * 2000-11-15 2004-02-19 주식회사 알엔에이 재조합 메탄올 자화 효모를 이용한 인간 페리틴의 대량생산 방법
WO2004057946A3 (fr) * 2002-12-23 2004-09-02 Max Planck Gesellschaft Procede de modification de la teneur en reserves de plantes
EP1709183A4 (fr) * 2003-12-12 2008-04-09 Univ Manitoba Methode pour modifier des phenotypes vegetaux avec de l'hemoglobine non symbiotique
US8084667B2 (en) 2003-12-12 2011-12-27 The University Of Manitoba Method of modifying plant phenotypes with nonsymbiotic hemoglobin
EP2613636A4 (fr) * 2010-09-08 2014-01-22 Childrens Hosp & Res Ct Oak Supplément alimentaire et procédés pour l'utiliser
US9063147B2 (en) 2011-12-30 2015-06-23 Slo-Iron, LLC Methods for isolation, use and analysis of ferritin
US20190241902A1 (en) * 2005-10-12 2019-08-08 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
CN115927382A (zh) * 2022-10-18 2023-04-07 合肥工业大学 一种用于增强植物铁积累且耐缺铁胁迫的编码基因的应用
WO2024003668A1 (fr) 2022-06-29 2024-01-04 Moolec Science Limited Expression élevée de protéine héminique animale dans des plantes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102084007B1 (ko) * 2018-11-09 2020-03-03 동아대학교산학협력단 식물의 철 흡수 효율을 증진시키는 호박벌 유래 페리틴 유전자 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016634A1 (fr) * 1991-03-22 1992-10-01 Novo Nordisk A/S Procede de production de proteines hemiques
WO1993019195A1 (fr) * 1992-03-20 1993-09-30 Novo Nordisk A/S Procede de production de proteines hemiques
WO1993025697A1 (fr) * 1992-06-15 1993-12-23 California Institute Of Technology Renforcement de la croissance des cellules par expression de proteines clonees fixatrices d'oxygene
WO1998012913A1 (fr) * 1996-09-26 1998-04-02 Bailey James E Expression de proteines globines dans des plantes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016634A1 (fr) * 1991-03-22 1992-10-01 Novo Nordisk A/S Procede de production de proteines hemiques
WO1993019195A1 (fr) * 1992-03-20 1993-09-30 Novo Nordisk A/S Procede de production de proteines hemiques
WO1993025697A1 (fr) * 1992-06-15 1993-12-23 California Institute Of Technology Renforcement de la croissance des cellules par expression de proteines clonees fixatrices d'oxygene
WO1998012913A1 (fr) * 1996-09-26 1998-04-02 Bailey James E Expression de proteines globines dans des plantes

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. J., Vol. 305, (1995), VAN WAYTSWINKEL O. et al., "Purification and Characterisation of Recombinant Pea-Seed Ferritins Expressed in Escherichia Coli: Influence of N-Terminus Deletions on Protein Solubility and Core Formation In Vitro", pages 253-261. *
CHEMICAL ABSTRACTS, Vol. 127, No. 16, 1997, Abstract No. 215964u; & JP,A,09 201 190. *
MOLECULAR & GENERAL GENETICS, Vol. 214, (1988), KHOSLA C. and BAILEY J.E., "The Vitreoscilla Hemoglobin Gene: Molecular Cloning, Nucleotide Sequence and Genetic Expression in Escherichia Coli", pages 158-161. *
MOLECULAR & GENERAL GENETICS, Vol. 214, (1988), LANDSMANN J. et al., "Organ Regulated Expression of the Parasponia Andersonii Haemoglobin Gene in Transgenic Tobacco Plants", pages 68-73. *
NATURE BIOTECHNOLOGY, Vol. 15, (1997), HOLMBERG N. et al., "Transgenic Tobacco Expressing Vitreoscilla Hemoglobin Exhibits Enhanced Growth and Altered Metabolite Production", pages 244-247. *
NATURE, Vol. 331, (1988), BOGUSZ D. et al., "Functioning Haemoglobin Genes in Non-Modulating Plants", pages 178-180. *
PLANT MOLECULAR BIOLOGY, Vol. 19, (1992), LOBREAUX S. et al., "Iron Induces Ferritin Synthesis in Maize Plantlets", pages 563-575. *
PLANT MOLECULAR BIOLOGY, Vol. 24, (1994), TAYLOR E.R. et al., "A Cereal Haemoglobin Gene is Expressed in Seed and Root Tissues Under Anaerobic Conditions", pages 853-862. *
PLANT PHYSIOLOGY, Vol. 115, (1997), ARREDONDO-PETER R. et al., "Rice Hemoglobins", pages 1259-1266. *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 30, (1990), RAGLAND M. et al., "Evidence for Conservation of Ferritin Sequences Among Plants and Animals and for a Transit Peptide in Soybean", pages 18339-18344. *
TRANSGENIC RESEARCH, Vol. 7, (1998), GOTO F. et al., "Iron Accumulation in Tobacco Plants Expressing Soyabean Ferritin Gene", pages 173-180. *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372961B1 (en) 1998-08-20 2002-04-16 Pioneer Hi-Bred International, Inc. Hemoglobin genes and their use
KR100419530B1 (ko) * 2000-11-15 2004-02-19 주식회사 알엔에이 재조합 메탄올 자화 효모를 이용한 인간 페리틴의 대량생산 방법
WO2004057946A3 (fr) * 2002-12-23 2004-09-02 Max Planck Gesellschaft Procede de modification de la teneur en reserves de plantes
US7807870B2 (en) 2002-12-23 2010-10-05 Max-Planck-Gesellschaft Method for altering the content of reserve substances in plants
EP1709183A4 (fr) * 2003-12-12 2008-04-09 Univ Manitoba Methode pour modifier des phenotypes vegetaux avec de l'hemoglobine non symbiotique
US8084667B2 (en) 2003-12-12 2011-12-27 The University Of Manitoba Method of modifying plant phenotypes with nonsymbiotic hemoglobin
US20190241902A1 (en) * 2005-10-12 2019-08-08 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US10696979B2 (en) * 2005-10-12 2020-06-30 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US11021714B2 (en) 2005-10-12 2021-06-01 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US11034973B2 (en) 2005-10-12 2021-06-15 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US11459580B2 (en) 2005-10-12 2022-10-04 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US11761014B2 (en) 2005-10-12 2023-09-19 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
US11814635B2 (en) 2005-10-12 2023-11-14 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics in response to cold
EP2613636A4 (fr) * 2010-09-08 2014-01-22 Childrens Hosp & Res Ct Oak Supplément alimentaire et procédés pour l'utiliser
US9063147B2 (en) 2011-12-30 2015-06-23 Slo-Iron, LLC Methods for isolation, use and analysis of ferritin
WO2024003668A1 (fr) 2022-06-29 2024-01-04 Moolec Science Limited Expression élevée de protéine héminique animale dans des plantes
US12359214B2 (en) 2022-06-29 2025-07-15 Moolec Science Limited High expression of animal heme protein in plants
CN115927382A (zh) * 2022-10-18 2023-04-07 合肥工业大学 一种用于增强植物铁积累且耐缺铁胁迫的编码基因的应用

Also Published As

Publication number Publication date
EP1007681A1 (fr) 2000-06-14
JP2001509385A (ja) 2001-07-24
AUPO776697A0 (en) 1997-07-31
CA2295202A1 (fr) 1999-01-21

Similar Documents

Publication Publication Date Title
US7154026B2 (en) Manipulation of cellulose and/or β-1,4,-glucan
US7834248B2 (en) Plant seed comprising vernolic acid
US7700826B2 (en) Genes encoding wheat starch synthases and uses thereof
EP0975765B1 (fr) Genes d'epoxygenase vegetale d'acide gras et utilisation de ces genes
EP2471808B1 (fr) Protéines liées à la forme de grain et la forme de feuille de riz, gènes codants et utilisations de celles-ci
Shyr et al. Glyphosate selected amplification of the 5-enolpyruvylshikimate-3-phosphate synthase gene in cultured carrot cells
EP1007681A1 (fr) Procede pour augmenter la teneur en fer des cellules des plantes
US6613745B1 (en) Therapeutic molecules derived from snake venom
CN101107364A (zh) 产率增加的植物及其制备方法
EP2078088B1 (fr) Amélioration de la productivité de grains de plantes par l'intermédiaire de la modulation de l'activité glutamine synthétase
US9006518B2 (en) F-box protein targeted plant oil production
WO2000037645A2 (fr) Acides nucleiques intervenant dans le cycle cellulaire, polypeptides et leurs utilisations
WO2000047614A1 (fr) Plantes transgeniques a expression modifiee de la proteine dp
CN113897372B (zh) OsFWL7基因在增加水稻籽粒金属微量元素含量中的应用
AU8199598A (en) Method of increasing the iron content of plant cells
CN101180398A (zh) 具有增加的产量的植物及其生产方法
WO1998007836A1 (fr) Manipulation de la biosynthese de proanthocyanidine
EP2048235A2 (fr) Alpha-N-acétylglucosaminidase synthétique de mammifère et séquences génétiques codant pour celle-ci
CN115216455B (zh) Enb1基因及其编码蛋白在调控植物籽粒大小和粒重中的应用
EP1115277A1 (fr) Nouveau procede de regulation du developpement de graines chez des vegetaux et sequences genetiques utiles a cet effet
US20020026658A1 (en) Genes encoding sinapoylglucose: malate sinapoyltransferase and methods of use
AU2012216826B2 (en) F-box protein targeted plant oil production
AU758678B2 (en) Plant sugar sensors and uses thereof
WO2000044780A1 (fr) Polypeptide capable de se lier au mannose et utilisations
CN107022016A (zh) 一种调控植物贮藏蛋白分选的蛋白质GmGPA3及其编码基因与应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 1999 242564

Country of ref document: US

Date of ref document: 19990219

Kind code of ref document: A

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 81995/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2295202

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09479318

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998931829

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998931829

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998931829

Country of ref document: EP